These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2010-020402-15 Randomised, double-blind, cross-over Phase III study to investigate the efficacy and safety of oxycodone after once daily administration of Oxycodone HCl XL tablets in comparison to twice daily admini... 2012-02-07 due-trials
Reported results 2011-004471-37 Randomised, double-blind, cross-over Phase III study to investigate the efficacy and safety of hydromorphone after once daily administration of Hydromorphone HCl PR tablets XL in comparison to twice d... 2012-08-31 due-trials
Reported results 2012-003218-14 Randomised, double-blind, placebo-controlled, parallel-group design, multi-centre, dose-escalation phase III trial to investigate the efficacy, safety, and tolerability of Naloxone HCl PR tablets admi... 2014-08-19 due-trials
Reported results 2012-004311-31 Randomised, double-blind, placebo-controlled, parallel-group design, multi-centre, dose-escalation phase III trial to investigate the efficacy, safety, and tolerability of Naloxone HCl PR tablets admi... 2015-06-16 due-trials
Reported results 2014-004535-40 Prospective, single-blind, placebo-controlled, three-treatment, three-period, adaptive multi-centre Phase IIa (proof-of-concept) trial to investigate the efficacy, safety, and tolerability of Ketamine... 2016-06-22 due-trials
Listed as ongoing, but also has a completion date and reported results 2015-002310-72 Open-label, uncontrolled trial to evaluate pharmacokinetics of naloxone in children from 4 to less than 18 years of age with opioid-induced constipation Nyílt, nem kontrollált vizsgálat a naloxone ... 2019-12-27 bad-data
Reported results 2017-000657-39 Randomised, double-blind, placebo-controlled, parallel-group, multi-centre, phase III trial to investigate the efficacy, safety and tolerability of Naloxone HCl PR Tablets in patients with opioid indu... 2019-05-02 due-trials